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Abstract
Background: Significant interest exists in establishing radiologic imaging as a valid biomarker for assessing the
response of cancer to a variety of treatments. To address this problem, we have chosen to study patients with
metastatic colorectal carcinoma to learn whether statistical learning theory can improve the performance of
radiologists using CT in predicting patient treatment response to therapy compared with the more traditional
RECIST (Response Evaluation Criteria in Solid Tumors) standard.
Results: Predictions of survival after 8 months in 38 patients with metastatic colorectal carcinoma using the
Support Vector Machine (SVM) technique improved 30% when using additional information compared to WHO
(World Health Organization) or RECIST measurements alone. With both Logistic Regression (LR) and SVM, there was
no significant difference in performance between WHO and RECIST. The SVM and LR techniques also demonstrated
that one radiologist consistently outperformed another.
Conclusions: This preliminary research study has demonstrated that SLT algorithms, properly used in a clinical
setting, have the potential to address questions and criticisms associated with both RECIST and WHO scoring
methods. We also propose that tumor heterogeneity, shape, etc. obtained from CT and/or MRI scans be added to
the SLT feature vector for processing.
Background
A major goal of this paper is to describe an ongoing
research effort to ascertain the most important lesion
features that change over time as rendered on Com-
puted Tomography (CT), as well as other imaging mod-
alities, using statistical learning theory (SLT) and
complex adaptive system (CAS) paradigms, to reliably
and reproducibly predict patient outcomes in response
to targeted therapies for metastatic colorectal carcinoma.
There is currently a great deal of interest in the estab-
lishment of radiologic imaging as a valid biomarker
for assessing the response of cancer to a variety of
treatments [1-8]. Imaging holds the promise of serving
as an earlier, more accurate predictor of patient out-
comes than serologic or clinical parameters [2,5,8-10].
CT is the most widely used imaging modality to assess
the change in patient tumor burden using quantitative
measures of tumor lesion volume such as the two
dimensional WHO [11] or one dimensional criteria
Response Evaluation Criteria in Solid Tumors (RECIST)
[12] used to measure patient response.
Little work has been done in validating imaging as a
surrogate endpoint for patient overall survival in
response to the many new therapies that are being
developed to treat advanced cancer in patients on
defined protocols or for the vastly larger pool of patients
having imaging used to assess their likely outcome in
response to established therapies. To date there has
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reproducible metrics of tumor response validated by a
high level of performance in predicting patient outcome
at individual sites or collaborating sites regionally or
nationally. Difficulties arise in the logistics of having
radiologists reproducibly use similar terms and methods
of measuring lesion change [13], and in relating imaging
findings to patient outcome [14-16]. Most prior work
has been directed at measuring lesion size on CT with
RECIST and WHO (World Health Organization) mea-
surements [11,12], and more recently with 3-D volu-
metric analyses [17-22] without considering how change
in size relates to outcome. Other information contained
on CT and magnetic resonance imaging (MRI) scans
regarding lesion appearance (including perfusion, tracer
activity, margins, and internal features) has not been
addressed adequately [23-25].
RECIST 1.1, the current standard [26] used to evaluate
treatment response for patients on new protocols for
cancer, is a semi-quantitative scoring system which con-
siders only existing lesion size change measurements
and interval development of new lesions in placing
patients into different response categories. Recently
Positron Emission Tomography (PET) and PET fused
with CT (PET/CT) have been used to assess cancer
r e s p o n s e ,b u tt h es a m ei s s u e so fr e p r o d u c i b l yr e l a t i n g
and validating imaging findings with regard to patient
outcome are present.
We have chosen to study patients with metastatic col-
orectal carcinoma for this pilot project to learn whether
statistical learning theory can improve the performance
of radiologists using CT in predicting patient treatment
response to therapy compared with the more traditional
RECIST standard. CT is currently the most commonly
used imaging modality to evaluate response to treatment
of a variety of solid tumors including colorectal carci-
noma. Colorectal carcinoma arises from the epithelial
lining cells of the large intestine. Systemic chemother-
apy, with or without surgery and radiation becomes the
treatment of choice for patients with metastatic disease.
Survival in these patients is usually short, but therefore
readily measurable as a marker for the success or failure
of different treatments. Various new therapies are being
developed to improve survival, which have assorted
mechanisms of action including angiogenesis modula-
tors and epidermal growth factor inhibitors, which can
be evaluated by imaging biomarkers. More accurately
predicting patient outcome in patients early in the
course of therapy has the potential to accelerate drug
development in phase II and phase III trials, improve
patient survival, and avoid prolonged potentially toxic
therapies in patients unlikely to do well. This research
project considers CT and colon cancer but our methods
of analyzing imaging results is readily applied to other
modalities (e.g., PET/CT, MRI) and other types of
malignancies.
RECIST (Response Evaluation Criteria in Solid
Tumors) [14] and its predecessors, primarily the WHO
method [11,27], define standard measurement methods
for converting visual image observations into a quantita-
tive and statistically tractable framework for measuring
tumor size response to therapy. The RECIST criteria
were modified in 2000 [12] to make measurement prac-
tices procedurally more consistent across multiple trials
and accommodate improvements in CT and MRI scan-
ners. Each method uses a pragmatically simplistic tech-
nique, which is dependent on observer judgment, to
determine lesion boundaries. WHO defines its tumor
measurement by summing a group of individual masses,
each of which is assessed by the cross product of its
greatest diameter and largest perpendicular diameter.
RECIST uses a linear measure. RECIST was designed to
be sufficiently aligned with past WHO practices such
that no major discrepancy would occur in the partial
response between the old and new guidelines, while spe-
cifying procedures on such items as the maximum num-
ber of solid tumor lesions that should be measured [28]
and the maximum number of lesions measured in any
one organ [29]. RECIST target lesions have to be
acquired with image slice thicknesses no larger than one
half the diameter of the measured lesion, which results
in recommending that 10-mm objects be imaged with
5-mm image slice thicknesses, while limiting measurable
target lesions to no smaller than 10mm except under
special circumstances. After target lesions are measured
using either single linear summation (RECIST) or the
bilinear product approach (WHO), the results are subse-
quently assigned to response-defined categories of com-
plete response (CR), partial response (PR), stable disease
(SD), and progressive disease (PD). By an apparently
subjective criteria, RECIST defined PR as a more than
30% linear decrease of the linear sums of the target
lesions (thus, by extrapolation, implying a 65% volu-
metric decrease) and PD as a more than 20% increase
(implying a 73% volumetric increase). This contrasts
with WHO criteria, in which those boundaries were set
volumetrically at 65% and 40%, respectively [30].
Because RECIST was framed in the context of indivi-
dual slices (and generally axial in the case of CT) the
research community is currently re-exploring the
obvious gaps in both RECIST and WHO criteria, which
are constrained by the limits of earlier technology. Little
attention has been paid to acknowledging inter and
intra observer variability. That is, the reader makes his/
her measurements unassisted by anything other than the
most rudimentary form of image-processing technology
( o f t e ns i m p l yt h eu s eo fe l e c t r o n i cc a l i p e r so naw o r k -
station display), resulting in significant differences
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Aside from suggesting the value of multiple independent
observers, current approaches are hardly likely to
improve decision making consistency on fuzzily
bounded objects. Neither RECIST nor WHO provide
especially rigorous guidance on the subject of observer
variability aside from recommending review panels and
independent observers. Disagreement among observers
[30,31] has been noted to be as high as 15% to 40% in
these contexts and may not be ideally remedied by con-
sensus or tie preventing arrangements. In fact, there is
little scientific literature that resolves the question of
what would constitute a sufficient number of observers
[32,33]. To minimize reader variation, three observers
have generally been employed. This odd-numbered
arrangement offers a pragmatic means of averaging data
and avoiding a tie, but has no theoretical basis. Larger
numbers of readers may permit some greater level of
certainty but is impractical or unaffordable in a real-
world context. Furthermore, providing only nominal
guidance on slice thickness, RECIST does not address at
any length image acquisition components that inevitably
result in significant lesion contrast differences within
and between studies.
However, RECIST has served a useful historic purpose
in grouping image data into the four response classifica-
tions (CR, PR, SD, PD). Since diameter measurements
are best determined on smoothly shaped, distinct tumor
boundaries—an ideal circumstance encountered infre-
quently—measurement variability inherent in such judg-
ments is not adequately reflected in the recorded data
a n di st h e r e f o r eac o n f o u n d e rt h a tc a n n o tb ec o r r e c t e d
systematically. Tumors with irregular or diffuse bound-
aries pose the most significant challenge to data extrac-
tion and are highly observer dependent.
Despite these recognized limitations, studies con-
tinue to be directed towards refining the RECIST
paradigm by minor, incremental modifications. This
is a major reason for proposing this new SLT technol-
ogy, which can take advantage of the new feature vec-
tor components resulting from these newer imaging
modalities, such as CT and MRI.Feature vector compo-
nents are the elements of the input vector used by the
statistical learning theory algorithms in arriving at an
intelligent decision.
Finally, the National Cancer Institute (National Insti-
tutes of Health, Bethesda, MD) Cancer Treatment Eva-
luation Program in its review of proposed trials
acknowledges both WHO criteria and RECIST as useful
for estimating tumor size response to therapies, but
neither mandates nor requires either for use in its spon-
sored clinical trials.
Consequently, we propose to use Complex Adaptive
Systems (CAS) and SLT to develop and test intelligent
post processing software to address these problems.
This software is designed, in part, to identify False Posi-
tive (FP) and False Negative (FN) errors. Patients that
fall into the FN error group should have been treated
but were not while the patients that fall into the FP
error category needlessly suffer the morbidity of treat-
ment as well as generating significant, unnecessary treat-
ment cost. Consequently, both type I (FP) and type II
(FN) errors are significant and should be minimized,
which is possible with the proposed STL algorithms that
adapt to the environment by using a feedback mechan-
ism to develop intelligent emergent interpretation beha-
vior by radiologists.
Results
RECIST, WHO individually and with additional information
Eight experiments were designed to measure the indivi-
dual Performance SLT accuracy of RECIST and WHO
as well as RECIST and WHO SLT improved perfor-
mance with additional information. These experiments
use the “one hold out” cross-validation technique
because the validation sets for 5-fold cross-validation
did not contain enough samples for statistically valid
conclusions. Two SLT paradigms were used: a non-
linear support vector machine (SVM) that employed a
sigmoid mapping kernel, and a linear Logistics Regres-
sion (LR) approach.
The SVMs were manually trained by an iterative pro-
cess rather than using an Evolutionary Programming
(EP) approach, which if implemented may have resulted
in an improved SVM system performance. The authors
have developed and EP / Evolutionary Strategies (ES)
SVM hybrid (EP/ES-SVM hybrid) that efficiently ascer-
tains, by an optimal search mechanism, the optimal
mapping kernel parameters used in mapping the feature
data from the non-linear input space to the linear fea-
ture space. This hybrid was not used in this analysis
because the software package used to configure the
dataset for experiments, perform the SVM and LR tech-
niques, and then run the Receiver Operator Characteris-
tic (ROC) analysis did not contain the ability to use
these advanced EP/ES-SVM theories. Rather, an iterative
process of manually changing the SVM parameters in
small steps was employed. Orange, the software package
used, acts as a wrapper for the well known LIB SVM
libraries, but does not offer any optimization algorithms.
This software package requires the user to ascertain, by
experiment, the mapping kernel parameters which result
in the best possible performance.
The group evaluated included 38 patients with meta-
static colon cancer treated with a last line therapy
(cetuximab and irinotecan), who had a median survival
of 8 months. Survival was used as the gold standard
diagnosis for Measures of Performance (MOP). A good
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and a poor response was considered death at or prior to
8 months (TN). The experiments had either 114, 38, or
31 samples, which were representative of the 114
lesions, 38 patients who had at least one lesion, and 31
patients who had multiple lesions. When only one or
two lesions per patient are used, lesions were selected at
random. The total feature vector length contained 35
components, where each experiment utilized subset ele-
ments of this feature vector. Table 1 depicts the infor-
mation content for these eight experiments: four for
RECIST and four for WHO, and delineates the number
and type of feature(s) used as well as the sample size.
Area under the ROC curve (AUC) performance results
for the four RECIST only and the four WHO only
experiments are depicted in figure 1. Figure 1 contains
4c u r v e s .C u r v e s1a n d2a r eA U CS V Ma n dL Rv a l u e s
for RECIST only, while curves 3 and 4 are the SVM and
LR results for WHO only. In general, this set of studies
showed the following:
￿ SVM performance for both RECIST and WHO are
better than the LR performance for all experiments
(compare curves 1 and 2 to curves 3 and 4). This is an
expected result because the SVM paradigm captures
predictive and discriminating information “hidden” in
the non-linear regions of the input space, where the LR
paradigm, because of its linear processing only, cannot
“see” this discriminating information.
￿ RECIST performed slightly better than WHO for
experiments 1, 2 and 3, but out performed WHO in
Experiment 4, when using SVM processing (compare
curves 2 and 4). {Note: Remember that two sets of
4 experiments were performed: 4 for RECIST and 4 for
WHO}.This means that including more patients (diver-
sity) with only one lesion has more predictive power
than including less patients with 2 or more lesions, at
least for this population. This preliminary result may
disagree with intuition, which says that more lesions/
patient provides more information. However, with these
non-linear algorithms perhaps the manner in which the
feature vector components interact and their informa-
tion diversity may be more significant than the number
of lesions/patient processed. This is an area for further
research study using experimental sensitivities.
￿ Both RECIST and WHO alone performed equally,
but with a fair to poor AUC of 0.61 using the non-linear
kernelized SVM paradigm. (See Experiment 1 for curves
1 and 3).
￿ Logistics Regression (LR) performed worse, espe-
cially with RECIST, when using 2 lesions per patient
compared to using just 1 lesion. This may be because
more patients complicated the structure of the input
space, thereby making it more non-linear because of
coupling effects. Consequently, the linear RECIST mea-
sures cannot capture the information in these non-linear
regions, but WHO can with a higher resultant AUC of
~0.65. This may be because WHO defines its tumor
measurement by summing a group of individual masses;
each lesion is assessed by the cross product of its great-
est diameter and its largest perpendicular bisector, a
mathematical operation that contains a non-linear com-
ponent. This is also a topic for further investigation.
￿ Experiment 2, where all lesions are processed inde-
pendent of patient, provides the least improvement
between LR and SVM processing when compared to the
Table 1 List of Experiments for Lesion Measurement Standards
Experiment
#
Features #o f
features
#o f
samples
1 RECIST Size Change or WHO Size Change only for 1 Lesion by Both Observers 4 38
2 # of Lesions per Patient, RECIST Size Change or WHO Size Change only, and Visual Size Change by Both
Observers
9 114
3 # of Lesions per Patient, New Lesions, RECIST Size Change or WHO Size Change only, and Visual Size Change
for 2 Lesions by Both Observers
17 31
4 # of Lesions per Patient, New Lesions, RECIST Size Change or WHO Size Change, and Visual Size Change for
1 Lesion by Both Observers
11 38
Experimental designs to ascertain performance accuracy for RECIST and WHO
Figure 1 Results of Lesion Measurement Standards
Experiments RECIST and WHO Performance Resulting From Non-
Linear Support Vector Machine (SVM) and Linear Logistics
Regression (LR) Processing. We propose establishing and quantifying
continuous MOPs to replace the four discrete RECIST and WHO
MOPs currently in use
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WHO only), as well as when using additional informa-
tion (See Experiments 3 and 4). That is, SVM processing
for Experiment 2 increased the AUC for both RECIST
and WHO performance from ~0.65 to ~0.69 (a ~7%
improvement). However, the SVM processing for
Experiments 3 and 4 increased performance, when com-
pared to RECIST and WHO alone, by an average of
~25% (increase from ~0.62 to ~0.78 AUC average
improvement) for Experiment 3 and an average
improvement of ~23% (increase from ~0.66 to ~0.81
AUC average improvement) for Experiment 4 (see aver-
age of experimental values for curves 1 and 3.) This is
also a topic for further research.
￿ Note the negatively correlated LR values for Experi-
ment 1. This result occurred for both RECIST and
WHO, and is again a reflection of the fact that linear
processing techniques cannot capture information “hid-
ing” in the non-linear region of the solution space. Note
that the non-linear processing provided by the SVM for
both RECIST and WHO using only these feature inputs
resulted in a ~0.61 AUC. This result says that, when
compared to Experiments 2 through 4, both the basic
R E C I S Ta n dW H Ob e n e f i t e df r o ma d d i t i o n a li n f o r m a -
tion added in the input feature vector. This result
implies adding imaging components to the feature vec-
tor should also increase performance and we will quan-
tify this measured improvement.
￿ Because of the marginal SVM and LR results from
Experiment 1, we are actively investigating (and devel-
oping) other MOPs which might be more sensitive to
RECIST and WHO measurements, when supplemented
with additional information, as was done in Experiments
3 and 4. This is an ongoing research effort.
￿ We have the capability to evaluate the efficacy of
drug treatment related to vascularity and lesion
enhancement. However, initial lesion enhancement
experiments did not improve performance for the cases
studied.
￿ In summary, we suggest that this preliminary
research study has demonstrated that these SLT algo-
rithms, properly designed, tested, evaluated and properly
used with a computer in a clinical setting, has the
potential to address those questions discussed in section
1.1 as well as those problems delineated in section 1.2.
We also suggest that tumor heterogeneity and shape,
etc, obtained from CT and/or MRI scans, be added to
the feature vector for processing. This will be a simple
process when the data is available.
Observer variability
We have previously discussed (see Background), lack of
rigorous guidance for RECIST and WHO regarding obser-
ver variability except from recommending panels and
independent observers. We hypothesize that both SLT
and CAS can help in reducing observer interpretive varia-
bility by: (1) using automated intelligent computer proces-
sing, and (2) training observers using SLT paradigm
outputs. That is, CAS and SLT do not make subjective
judgments: they adapt to the environment by developing
emergent behavior using only factual information con-
tained in the feature vector and will adapt differently when
this information content is altered in some way. They also
recognize and better adapt to the more accurate informa-
tion content contained in the feature vector. This is illu-
strated by the three experiments described in table 2,
whose content is similar to that described in table 1.
Figure 2 shows both SVM and LR SLT results for
table 2 experiments for two observers, using the same
data set described above. Two results are immediately
clear: (1) Observer 2 has the best MOPs for predicting
patient survival as expected being the more experience
observer (three years of training compared to only one
for Observer 1), and (2) SVM processing provided more
accurate AUC results than LR, which is an expected
result. However, another observation is that the SVM
(and other) results can possibly be used to improve
Observer 1’s performance by designing a set of sensitiv-
ity experiments to establish which inaccurately “read”
feature values are most significantly contributing to per-
formance denegation, and train Observer 1 using this
information.
Finally, this set of observer variability experiments
shows that Experiment 3 provides the most accurate
results, which is consistent with the AUC results found
in the previous set of experiments.
Table 2 List of Experiments for Observer Variability
Experiment
#
Features #o f
features
#o f
samples
1 # of Lesions per Patient, RECIST Size Change, WHO Size Change, and Visual Size Change for 1 Lesion by
Observer 1 or Observer 2 only
7 114
2 # of Lesions per Patient, RECIST Size Change, WHO Size Change, and Visual Size Change for 2 Lesions by
Observer 1 or Observer 2 only
13 31
3 # of Lesions per Patient, New Lesions, RECIST Size Change, WHO Size Change, and Visual Size Change for 1
Lesion by Observer 1 or Observer 2 only
83 8
Experimental design to ascertain observer variability
Land et al. BMC Genomics 2010, 11(Suppl 3):S15
http://www.biomedcentral.com/1471-2164/11/S3/S15
Page 5 of 11Conclusions
Eight experiments were designed to measure the indivi-
dual performance SLT accuracy of RECIST and WHO
as well as RECIST and WHO SLT improved perfor-
mance with additional information. These experiments
used the “one hold out” cross-validation technique
because the validation sets for 5-fold cross-validation
did not contain enough samples for statistically valid
conclusions. Two SLT paradigms were used: a non-lin-
ear support vector machine (SVM) that employed a sig-
moid mapping kernel and a linear Logistics Regression
(LR) approach. The group evaluated included 38
patients with metastatic colon cancer treated with a last
line therapy (cetuximab and irinotecan), who had a
median survival of 8 months. Survival was used as the
gold standard diagnosis for MOP. A good response was
considered survival beyond 8 months (TP) and a poor
response was considered death at or prior to 8 months
(TN). The experiments performed resulted in the fol-
lowing general behavior:
￿ SVM performance for both RECIST and WHO are
better than the LR performance for all experiments.
This is an expected result because the SVM paradigm
captures predictive and discriminating information “hid-
den” in the non-linear regions of the input space, where
the LR paradigm, because of its linear processing only,
cannot “see” this discriminating information.
￿ We suggest that this preliminary research study has
demonstrated that these SLT algorithms, properly
designed, tested, evaluated and properly used with a
computer in a clinical setting, has the potential to
address those questions discussed in section 1.1 as well
as those problems delineated in section 1.2 . We also
suggest that tumor heterogeneity and shape, etc,
obtained from CT and/or MRI scans, be added to the
feature vector for processing.
￿ Two results for the observer variability experiments
were immediately clear: (1) Observer 2 has the best
MOPs for predicting patient survival as expected being
t h em o r ee x p e r i e n c eo b s e r v e r( t h r e ey e a r so ft r a i n i n g
compared to only one for Observer 1), and (2) SVM
processing provided more accurate AUC results than
LR, which is an expected result. However, another
observation is that the SVM (and other) results can pos-
sibly be used to improve Observer 1’s performance by
designing a set of sensitivity experiments to establish
which inaccurately “read” feature values are most signifi-
cantly contributing to performance denegation, and
train Observer 1 using this information.
￿ Finally, we have the capability to evaluate the effi-
cacy of drug treatment related to vascularity and lesion
enhancement. However, initial lesion enhancement
experiments did not improve performance for the cases
studied.
Methods
Summary of logistic regression, odds ratio and ROC
curves
Ordinary regression deals with finding a function that
relates a continuous outcome variable (dependent vari-
able y) to one or more predictors (independent variables
x1, x2, etc.). Simple linear regression assumes a function
of the form: y=c0 +c 1x1 +c 2x2 +Â …… and finds the
values of c0,c 1,c 2,e t c .L o g i s t i cr e g r e s s i o ni sav a r i a t i o n
of ordinary regression, useful when the observed out-
come is restricted to a dichotomous output, which
usually represents the occurrence or non-occurrence of
some outcome event, (usually coded as 1 or 0, respec-
tively). It produces a result that predicts the probability
of the occurrence as a function of the independent vari-
ables. Logistic regression fits a special sigmoidal curve
by taking the linear regression, which could produce any
y-value in the range [-∞,+ ∞] and transforming it with
the function: p=Exp(y)/( 1+E x p ( y)), which produces
p-values between 0 (as y approaches minus infinity) and
1 (as y approaches plus infinity). Consequently, this now
becomes a special kind of regression, which also pro-
duces Odds Ratios (OR) associated with each predictor
value. The odds of an event are defined as the probabil-
ity of the outcome event occurring divided by the prob-
ability of the event not occurring. The odds ratio for a
predictor tells the relative amount by which the odds of
the outcome increase (OR greater than 1.0) or decrease
(OR less than 1.0) when the value of the predictor is
increased by 1.0 units.
However, a problem exists with using OR alone [34].
The accuracy or validity of a binary marker for classify-
ing persons is better summarized in a case-control study
by reporting its true-positive fraction (TPF, also known
Figure 2 Results of Observer Variability Experiments. Observer
2 is the most accurate reader. We propose to train Observer 1 (and
other observers) using uniquely designed sensitivity experiments
process by our SLT algorithms.
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known as 1-specificity) These are defined as follows:
TPF = Prob.[marker positive | outcome positive] and
FPF = Prob.[marker positive | outcome negative].
Because there are two types of errors (misclassifying
positives and misclassifying negatives), the study results
should reflect both of these errors. A perfect marker
will have TPF = 1 and FPF = 0. Obviously, to have con-
fidence in the prediction that a marker makes, TPF and
FPF should be close to these ideal values. The general
public often expects that a marker offer reasonably
accurate classification and confident prediction. How-
ever, a marker can be useful even if FPF and TPF are
less than ideal. The criteria by which the marker is
judged useful depend entirely on the context in which it
is to be used. For example, a marker for screening a
healthy population for cancer needs to have an extre-
mely low FPF because workup procedures such as
biopsy that follow a positive screening test are generally
invasive and expensive. Given that cancer is a rare dis-
ease in the population tested, even a low FPF will result
in huge numbers of people undergoing unnecessary,
costly procedures. The odds ratio can be written as a
simple function of (FPF, TPF) [35,36]:
OR = (TPF / (1 – TPF))*((1 – FPF) / FPF)
The difficulty with this definition is that it depends
upon a specific threshold setting (as specific values of
TPF and FPF are required), and consequently the odds
ratio is a simple scalar measure of association between
marker and outcome. Therefore, OR values do not char-
acterize the discrimination between cases and controls
that can be achieved by a marker since an infinite num-
ber of pairs of TPFs and FPFs are consistent with a par-
ticular odds ratio value (because TPF is a continuous
mapping of FPF for a specific value of OR).
Consider the two density functions of a particular
test in two populations; where one population has a
disease (or some other meaning) and the other popula-
tion does not have a disease (or some other meaning).
One rarely observes a perfect separation between these
two density functions, but rather an overlap in the dis-
tribution of the test results, which give rise to both
false positive and false negative errors. ROC curves are
one way to measure the amount of overlap between
the probability density functions, and are built from
these two density functions by first constructing two
functions, where the first graph is hit rate (or sensitiv-
ity) as a function of threshold setting, while the second
graph is the false alarm rate (or 1 –specificity) as a
function of threshold setting. Then the hit rate is
plotted as a function of the false alarm rate using the
threshold value as the parameter. Finally, the AUC fol-
lows by numerical integration, which is bounded by 0
≤ AUC ≤ 1 and has the following meaning: 0.5, which
is equivalent to random guessing, and increasing to 1
for a perfect system. Therefore, the AUC (sometimes
called the AZ value) may be interpreted as the average
system performance as measured over all threshold
settings. Consequently, the ROC curve is the natural
generalization of (FPF, TPF) to accommodate settings
in which the marker is continuous. It describes the
whole set of potential (FPF, TPF) combinations possi-
ble with positivity criteria based on the marker. Chan-
ging the units in which the marker is measured has no
impact on its ROC curve in contrast to logistic regres-
sion models in which, as noted above, the odds ratio
must be interpreted according to a unit increase in the
value of X. Moreover, ROC curves provide a natural
common scale for comparing different markers even
when they are measured in completely different units.
In contrast, because odds ratios are interpreted per
unit increase in the marker, odds ratios for two mar-
kers may not be comparable. This is why we convert
the logistic regression probability density functions
into ROC curves for this paper.
Summary of logistic regression
Logistic regression is a multivariate extension of linear
regression, used for predicting a dichotomous outcome,
usually non-occurrence or occurrence of an event repre-
sented by 0 or 1 respectively [37].
Logit transformation As Y approaches 1 or 0, a one
unit change in X should have a smaller effect then when
Y is around 0.5. The varying change in Y based on the
magnitude of X is accomplished in logistic regression
with the Logit transformation. Let Pi be the probability
of event E occurring at Xi. Then the odds of E occurring
at Xi are Pi /( 1-Pi ). The Logit, or logged odds, is the
natural logarithm of the odds ln(Pi /( 1 - Pi)). The rela-
tionship of X to the Logit, or logged odds, is given by:
b0 + b1Xi = ln(Pi /( 1-Pi)),
where b0 is the intercept and b1 is the coefficient, such
that each unit change in X results in a b1 change in the
log odds. Consequently, it follows from the above for-
mula that X is related to the odds by:
Pi /(1 – Pi)=e
b0+b1Xi
T h em u l t i v a r i a t ef o r m u l af o rt h el o g g e do d d sw o u l d
then be
Pi /(1 – Pi)=e
b0+b1Xi1+b2Xi2+…bnXin
The probability may be calculated from Xi,t h ei n t e r -
cept and coefficients, as described in the expression
below:
Pi = e
b0+b1Xi1+b2Xi2+…bnXin /( 1+e
b0+b1Xi1+b2Xi2+…
bnXin)
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logistic regression ROC curves, where this development
will be subsequently described.
Log likelihood The log likelihood is used in the selec-
tion of the coefficients as well as a test of model fitness.
The likelihood of a model is Π{Pi
Yi *( 1– Pi)
1 –Yi}s u c h
that Pi is the calculated probability of the result being 1,
and Yi is the actual result for sample i. Note that the
likelihood is 1 for a perfect model where Pi =Y i such
that Y is in {0, 1}. To avoid minute values, logistic
regression uses the logged likelihood or
∑ {(Yi* ln(Pi)) + (1 – Yi) * ln(1 – Pi)}
As the likelihood function approaches 1, the log likeli-
hood approaches 0. The smaller the results of the likeli-
hood function, the further negative the log likelihood.
The closer the likelihood is to 1, the more representative
the coefficients and intercept are of producing the
observed results.
Intercept and coefficients The intercept and coefficients
are chosen to maximize the logged likelihood. The inter-
cept is first set to the base logged likelihood. The base
log likelihood is calculated with all coefficients set to
zero and Pi set to the probability of the outcome in the
sample set. The intercept and coefficients are then mod-
ified in an iterative fashion using the Newton-Raphson
method to achieve the maximum logged likelihood. The
solution is said to converge when the change in the log
likelihood is less than 10
-8 from the previous iteration.
Base log likelihood The base log likelihood is the value
where the model performs no better than chance. The
further the final log likelihood from the base log likeli-
hood the better the model fit. This distance is then mul-
tiplied by -2 giving a chi-square value with the degrees
of freedom equal to the number of independent
variables.
Converting PDFs into ROC curves We previously sta-
ted that the multivariate density functions given below
were used to formulate the ROC curves.
Pi = e
b0+b1Xi1+b2Xi2+…bnXin /( 1+e
b0+b1Xi1+b2Xi2+…
bnXin)
ROC curves developed directly from probability den-
sity functions eliminate the problems previously dis-
cussed using odds ratios as well as allow an “apples-to-
apples” comparison with ROC results developed by
more standard approaches. Th ep r o c e s si sa sf o l l o w s .
From either the null or alternate hypothesis density
function, compute the hit rate and false alarm rate as a
function of the threshold setting and from these two
functions construct the hit rate as a function of the false
alarm rate using the same activation threshold para-
meter. The area under the curve (AUC), or AZ value,
may then be computed by a trapezoidal integration.
Summary of support vector machines
Support vector machines (SVMs), as developed by Vap-
nik [38-42] are briefly summarized in this section. This
discussion is included to provide the theoretical expla-
nation for why it is possible to train SVMs to a global
minimum, and thereby provide better performance
accuracy, when compared to three layer artificial neural
network performance trained by back propagation.
Assume there exist N observations from a data set. Each
observation (or training example) consists of a vector xi
containing the input pattern and a corresponding
known classification yi. The objective of the learning
machine would be to formulate a mapping xi ® yi. Now
consider a set of functions f(x, a) with adjustable para-
meters a,t h a td e f i n eas e to fp o s s i b l em a p p i n g sx® f
(x, a). Here, x is given and a is chosen. In the case of a
traditional neural network of fixed architecture, the a
values would correspond to the weights and biases. The
quantity R(a), known as the expected (or true) risk,
associated with learning machines is defined as:
Ry f p y d x d y () (,) (,)  =− ∫
1
2
xx
where, p(x, y) is an unknown probability density func-
tion from which the examples were drawn. This risk
function is the expected (or true) value of the test (or
validation) error for a trained learning machine. It may
be shown that the best possible generalization ability of
a learning machine is achieved by minimizing R(a), the
Table 3 Feature Vector for Lesions or Patients
For Either Patient or Lesion Based Experiments
The following features could be used in both analyzing a patient as a whole or the lesions individually:
Num_Lesions Number of Lesions per Patient
T_ Overall Overall Visual Tumor Burden Change – Observer 1
C_Overall Overall Visual Tumor Burden Change – Observer 1
T-NewL Patient has New Lesions – Observer 1
C-NewL Patient has New Lesions – Observer 2
Features that could be used for either lesion or patient based experiments
Land et al. BMC Genomics 2010, 11(Suppl 3):S15
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Page 8 of 11expected (or true) risk. This generalization bound, for
binary classification, holds with the probability of at
least 1 - h (0 ≤ h ≤ 1) for all approximating functions
that minimize the expected (or true) risk.
RR
h
N
h
N
() ()
log log


≤+
⎛
⎝
⎜
⎞
⎠
⎟ +
⎛
⎝
⎜
⎞
⎠
⎟ − ⎛
⎝
⎜
⎞
⎠
⎟
⎛
⎝
⎜
⎜
⎜
⎜ ⎜
⎞
⎠
⎟
⎟
emp
2
1
4
⎟ ⎟
⎟ ⎟
The first term on the right hand side of the above
equation is known as the “empirical risk”,w h e r et h e
empirical risk Remp(a) is expressed by:
R
N
yf ii
i
N
emp() ( ,)  =−
= ∑
1
2
1
x
This function is a measure of the error rate for the
training set for a fixed, finite number of observations.
This value is fixed for a particular choice of a and a
given training set (xi, yi). The second term in the above
expression is the “Vapnik-Chervonenkis (VC) confidence
interval.” This term is a function of the number of train-
ing samples N, the probability value h and the VC
dimension h. The VC dimension is the maximum num-
ber of training cases that can be learned by a learning
machine without error for all possible labeling of the
classification functions f(x, a), and is, therefore, a mea-
sure of the capacity of the learning machine. In tradi-
tional neural network implementations, the confidence
interval is fixed by choosing a network architecture a
priori. The function is minimized by generally obtaining
a local minimum from minimizing the empirical risk
through adjustment of weights and biases. Consequently,
neural networks are trained based on the empirical risk
minimization (ERM) principle. In an SVM design and
implementation, not only is the empirical risk mini-
mized, the VC confidence interval also is minimized by
using the principles of structural risk minimization
(SRM). Therefore, SVM implementations simultaneously
minimize the empirical risk as well as the risk associated
with the VC confidence interval, as defined in the above
Table 4 Feature Vector for Lesions Only
Lesion Based Experiments
When lesions were analyzed individually, each lesion had the following:
T_ RECIST1 Baseline RECIST Size Change – Observer 1
C_RECIST1 Baseline RECIST Size Change – Observer 2
T _WHO1 Baseline WHO Size Change – Observer 1
C _WHO1 Baseline WHO Size Change – Observer 2
T_ RECIST2 Follow up CT RECIST Size Change – Observer 1
C_RECIST2 Follow up RECIST Size Change – Observer 2
T _WHO2 Follow up WHO Size Change – Observer 1
C _WHO2 Follow up WHO Size Change – Observer 2
T-Target Visual Tumor Change in Target Lesion – Observer 1
C-Target Visual Tumor Change in Target Lesion – Observer 2
Features that could be used for only individual lesion based experiments
Table 5 Feature Vector for Patients Only
Patient Based Experiments
Patients had from 1 to 6 lesions. Each lesion had the following features: (# denotes lesion number)
#-T_ RECIST 1 Baseline RECIST Size Change – Observer 1
#-C RECIST1 Baseline RECIST Size Change – Observer 2
#-T _WHO1 Baseline WHO Size Change – Observer 1
#-C _WHO1 Baseline WHO Size Change – Observer 2
#-T_ RECIST2 Follow up RECIST Size Change – Observer 1
#-C_RECIST2 Follow up RECIST Size Change – Observer 2
#-T _WHO2 Follow up WHO Size Change – Observer 1
#-C _WHO2 Follow up WHO Size Change – Observer 2
#-T-Target Visual Tumor Change in Target Lesion – Observer 1
#-C-Target Visual Tumor Change in Target Lesion – Observer 2
Features that could be used for only patient based experiments. No more than two lesions were selected per patient in any experiment
Figure 3 Probability Density Functions.
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® ∞, the empirical risk approaches the true risk
because the VC confidence interval risk approaches
zero. The reader may recall that obtaining larger and
larger sets of valid training data would sometimes pro-
duce (with a great deal of training experience) a better
performing neural network, which resulted from classi-
cal training methods. This restriction is not incumbent
on the SRM principle and is the fundamental difference
between training neural networks and training SVMs.
Finally, because SVMs minimize the true risk, they pro-
vide, when properly trained, a global minimum.
Summary of data set feature components and feature
vector construction
Seventy five potential features were available for use in
the experiments: (1) those that could be used for all
experiments, (2) those that could be used only for
experiments where the lesions were analyzed individu-
ally, and (3) those that could be used only for experi-
ments where the patient was being analyzed as a whole.
The features comprising the data set were empirically
determined and organized into a format suitable for sta-
tistical learning theory processing. While all the patients
had at least one lesion, only four had the full six lesions
possible in the feature vector. Table 3,4,5 depict the
name in the database of each feature, and a detailed
description of what that feature represents.
Applying statistical learning theory to access change in
tumor size in response to therapy using the basic RECIST
and WHO criteria with additional information
This preliminary research study documents SLT perfor-
mance for the following experiments: (1) RECIST and
WHO individually, (2) RECIST and WHO with addi-
tional information, and (3) observer variability using
RECIST and WHO. These SLT experiments use a basic
population MOP, which is the area under the ROC.
AUC is a quantitative population MOP as our current
objective is to establish the performance for a group of
patients, and later extend our SLT algorithms to indivi-
dual patient risk assessment by using, for example, epi-
demiological MOPs such as Odds Ratios, Relative and
Absolute Risk.
Figures 3 and 4 depict the definition of the density
f u n c t i o n sa sw e l la st h er e s u l t a n tf o r mo ft h eR O C
curve. This AUC could be used to supplement the cur-
rently used discrete RECIST and WHO categories of
complete response (CR), partial response (PR), stable
disease (SD), and progressive disease (PD).
TP, TN, FN, and FP are defined in table 6. Patients
that fall into the FP error category needlessly suffer the
morbidity of treatment as well as generating significant,
unnecessary treatment cost while the patients that fall
into the FN error category should have been treated but
were not. Consequently, both type I (FP) and type II
(FN) errors are significant and should be minimized,
which is possible with SLT algorithms that adapt to the
environment by using a feedback mechanism and
thereby intelligently develop emergent behavior.
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Table 6 Contingency Matrix for Patient Outcome Prediction
System Diagnosis
+-
Gold Standard
Diagnosis
+ TP (true positive) Patients that live with treatment after 8
month period as expected
FN (false negative) Patients that will live after 8 months with
treatment but are expected to die
- FP (false positive) Patients that die before 8 months with
treatment but are expected to live
TN (true negative) Patients that die with treatment before 8
month period as expected
Contingency Matrix identifying statistical decision density function processing definitions and the resultant clinical errors possible. The Gold Standard is the
correct outcome and the System Diagnosis is the prediction of outcome made
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